Skip to main content
. 2024 May 5;12(5):500. doi: 10.3390/vaccines12050500

Table 3.

Demographics and clinical characteristics of the subjects included in the primary studies (only cases in the first season).

Variable Studies No. of Subjects
(/Total, %)
No. of Placebo
(/Total, %)
RR (95% CI) Heterogeneity
I2 (95% CI) τ2 (95% CI) Q (p-Value)
Demographic data
Age > 70/75 years [48,51,52,80,81,82,83] 19,316/51,055
(37.83%)
19,216/50,876
(37.77%)
1000
(0.984; 1.015)
0.0%
(0.0; 79.2)
0.001
(0.001; 0.002)
0.18 (0.996)
White ethnicity [48,51,52,80,81,82,83] 38,034/51,055
(74.50%)
37,975/50,876
(74.64%)
0.996
(0.990; 1.003)
0.0%
(0.0; 79.2)
0.001
(0.001; 0.002)
2.09 (0.300)
Male Gender [48,51,52,80,81,82,83] 25,386/51,055
(49.72%)
25,056/50,876
(49.25%)
1.024
(0.987; 1.061)
71.2%
(27.1; 88.6)
0.001
(0.000; 0.056)
13.89 (0.008)
Comorbidities
COPD [48,51,52,82] 3322/49,979
(6.65%)
3379/50,148
(6.74%)
0.986
(0.942; 1.033)
0.0%
(0.0; 84.7)
0.001
(0.000; 0.024)
0.38 (0.945)
Congestive heart
disease
[48,51,52,82] 802/49,979
(1.60%)
815/50,148
(1.63%)
0.986
(0.896; 1.086)
0.0%
(0.0; 84.7)
0.001
(0.000; 0.015)
0.38 (0.945)
Asthma [48,52,82] 3000/32,576
(9.21%)
2871/32,463
(8.84%)
1.049
(0.999; 1.101)
0.0%
(0.0; 89.6)
0.001
(0.000; 0.014)
0.52 (0.772)